Frequently Asked Questions
The market is segmented based on By Type (Paraceptal, Pentrilobular and Panlobular), Mechanism of Action Type (Bronchodilators, Beta-agonists, Anticholinergics, Corticosteroids, Phosphodiesterase -4 Inhibitors and Mucolytics), Stages Type (Very Mild or Stage 1: FEV1 is About 80.0% of Normal, Moderate or Stage 2: FEV1 is Between 50.0% and 80.0% of Normal, Severe or Stage 3: FEV1 is Between 30.0% and 50.0% of Normal and Very Severe or Stage 4: FEV1 is Lower Than in Stage 3, or The Same as Stage 3 But With Low Blood Oxygen Levels), Therapy Type (Oxygen Therapy and Protein Therapy), Drug Type (Aclidinium, Formoterol, Salmeterol, Levalbuterol, Ipratropium, Olodaterol, Ffluticasone, Budesonide and Prednisolone), Route of Administration (Oral, Inhaled, Intravenous and Others), Surgery Type (Lung Volume Reduction Surgery and Lung Transplant Surgery), Device Type (Inhalers, Pressurized Metered-Dose Inhalers (MDIS) , Dry-Powder Inhalers (DPIS), Nebulizers and Soft Mist Inhalers), End Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
.
The Global Emphysema Drug Market size was valued at USD 4474.54 USD Million in 2022.
The Global Emphysema Drug Market is projected to grow at a CAGR of 6.3% during the forecast period of 2023 to 2030.
The major players operating in the market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company, Astrazeneca, Pfizer , Takeda Pharmaceutical Company Limited, Bristol,Myers Squibb Company, Sanofi, Bayer AG, AbbVie , Allergan, Precigen, Pulmonx Corporation, Halozyme, Mariposa Health, Kamada Pharmaceuticals, Olympus Corporation, Spiration, Lifetech Scientific.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.